Below are the most recent publications written about "Vesicular Monoamine Transport Proteins" by people in Profiles.
-
Caroff SN, Citrome L, Meyer J, Sajatovic M, Goldberg JF, Jain R, Lundt L, Lindenmayer JP, McEvoy JP, McIntyre RS, Tohen M, Ketter TA. A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. J Clin Psychiatry. 2020 Jan 28; 81(2).
-
Hedges DM, Obray JD, Yorgason JT, Jang EY, Weerasekara VK, Uys JD, Bellinger FP, Steffensen SC. Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway. Neuropsychopharmacology. 2018 05; 43(6):1405-1414.
-
Freudenreich O, Remington G. Valbenazine for Tardive Dyskinesia. Clin Schizophr Relat Psychoses. 2017 Summer; 11(2):113-119.
-
Cliburn RA, Dunn AR, Stout KA, Hoffman CA, Lohr KM, Bernstein AI, Winokur EJ, Burkett J, Schmitz Y, Caudle WM, Miller GW. Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain. J Chem Neuroanat. 2017 Oct; 83-84:82-90.
-
Zhang YH, Chu C, Wang S, Chen L, Lu J, Kong X, Huang T, Li H, Cai YD. The Use of Gene Ontology Term and KEGG Pathway Enrichment for Analysis of Drug Half-Life. PLoS One. 2016; 11(10):e0165496.
-
Xiong N, Li N, Martin E, Yu J, Li J, Liu J, Lee DY, Isacson O, Vance J, Qing H, Wang T, Lin Z. hVMAT2: A Target of Individualized Medication for Parkinson's Disease. Neurotherapeutics. 2016 07; 13(3):623-34.
-
Lohr KM, Chen M, Hoffman CA, McDaniel MJ, Stout KA, Dunn AR, Wang M, Bernstein AI, Miller GW. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals. Toxicol Sci. 2016 09; 153(1):79-88.
-
Alter SP, Stout KA, Lohr KM, Taylor TN, Shepherd KR, Wang M, Guillot TS, Miller GW. Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration. Exp Neurol. 2016 Jan; 275 Pt 1:17-24.
-
Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. Eur J Nucl Med Mol Imaging. 2016 Mar; 43(3):474-481.
-
Lohr KM, Stout KA, Dunn AR, Wang M, Salahpour A, Guillot TS, Miller GW. Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity. ACS Chem Neurosci. 2015 May 20; 6(5):790-9.